Energetic therapy for psycho-emotional conditions in children and adolescents with vegetative dystonia
DOI: 10.32364/2618-8430-2021-4-1-77-84
E.V. Neudakhin1, O.E. Talitskaya2
1V.F. Voino-Yasenetsky Research Practical Center for Children’s Specialized Medical Care, Moscow, Russian Federation
2Branch of LLC “Gazprom Transgaz Moscow” “Center for Diagnostics & Rehabilitation”, Moscow, Russian Federation
This paper discusses the evolution of the knowledge on some aspects of vegetative dystonia and psychosomatic conditions as well as the hierarchy of various organs and systems. The role of the immune system in the development of psychosomatic conditions is emphasized. The data on the specifics of psycho-emotional reactions in children depending on age and the type of underlying pathological condition are addressed. Adaptation compensatory role of emotions is highlighted. Chronic stress and impaired activity of enzymes contribute to the development of vegetative dystonia and associated psycho-emotional conditions. Carnitine is involved in metabolic processes from conception to aging. Multiple studies demonstrate high efficacy of energetic preparations (e.g., L-carnitine, coenzyme Q10 etc.) for psycho-emotional conditions in children with vegetative dystonia.
Keywords: children, stress, vegetative dystonia, neuroimmunoendocrinology, emotions, energetic therapy, L-carnitine.
For citation: Neudakhin E.V., Talitskaya O.E. Energetic therapy for psycho-emotional conditions in children and adolescents with vegetative dystonia. Russian Journal of Woman and Child Health. 2021;4(1):77–84. DOI: 10.32364/2618-8430-2021-4-1-77-84.
References
1. Shvarkov S.B. Features of vegetative dystonia in children. Autonomic disorders. Wayne A.M., ed. M.: Medical Information Agency; 1998:451–463 (in Russ.).
2. Vegetative dysfunction in children and adolescents. L.V. Kozlova, ed. M.: GEOTAR-Media; 2008 (in Russ.).
3. Neudakhin E.V. On the issue of autonomic disorders in children (in order to discuss the problems raised in the article by A.A. Kurochkin et al. "Neurocirculatory dystonia in children and adolescents — a disease or borderline state"). Pediatria. 2003;2:101–103 (in Russ.).
4. Neudakhin E.V. Introduction. In: Shilyaev R.R., Neudakhin E.V., eds. Children’s Vegetology. M.: "Medpractica-M"; 2008:12–14 (in Russ.).
5. Batysheva T.T., Zaitsev K.A., Sarzhina M.N. et al. Autonomic dysfunction syndrome in children and adolescents: clinical manifestations, diagnosis and treatment. Part No. 1: guidelines No. 25. M.; 2015 (in Russ.).
6. Vein A.M. Autonomic disorders: clinical picture, treatment, diagnosis. M.: Medical Information Agency; 2000 (in Russ.).
7. Kryzhanovsky G.N., Magaeva S.V. Pathophysiology of neuroimmune interactions. Pathogenesis. 2010;1:4–9 (in Russ.).
8. Samotrueva M.A., Yasenyavskaya A.L., Tsibizova А.A. et al. Neuroimmunoendocrinology: modern concepts of molecular mechanisms. Immunologiya. 2017;38(1):49–59 (in Russ.). DOI: 10.18821/0206-4952-2017-38-1-49-59.
9. Korneva E.A. Pathways of neuro-immune communication: past and present time, clinical application. Medical Immunology (Russia). 2020;22(3):405–418 (in Russ.). DOI: 10.15789/1563-0625-PON-1974.
10. Neudakhin E.V. Chronic stress in general paediatric pathology. Pediatric Nutrition. 2014;12(5):44–49 (in Russ.)
11. Zavadenko N.N., Nesterovsky Yu.E. Clinical manifestations and treatment of autonomic dysfunction syndrome in children and adolescents. Pediatria. 2012;91(2):93–101 (in Russ.).
12. Neudakhin E.V. Basic concepts of vegetative dystonia syndrome in children and principles of treatment. Paediatrician practice. 2018;2:5–10 (in Russ).
13. Pankov D.D., Rumyantsev A.G. On the question of the definition of the terms "neurocirculatory dystonia" and "borderline state". Pediatria. 2003;2:98–100 (in Russ.).
14. Kryzhanovsky G.N. Determinant structures in the pathology of the nervous system. M.: Medicine; 1980 (in Russ.).
15. Dyukova G.M., Vein A.M. Autonomic dystonia syndrome. In: Golubev V.L., ed. Vegetative disorders: clinical picture, treatment, diagnosis: a guide for doctors. M.: Medical Information Agency; 2010:114–130 (in Russ.).
16. Antropov Yu.F., Shevchenko Yu.S. The role of affective disorders in the development of psychosomatic disorders in children. In: Shilyaev R.R., Neudakhin E.V., eds. Children’s Vegetology. M.: "Medpractica-M"; 2008:41–80 (in Russ.).
17. Sudakov K.V. Systemic mechanisms of emotional stress. M.: Medicine; 1981 (in Russ.).
18. Neudakhin E.V., Gromova S.V., Karmanov M.E. Peculiarities of psi-hovegetative homeostasis in adolescents with primary hypogonadism. In: Shilyaev R.R., Neudakhin E.V., eds. Children’s Vegetology. M.: "Medpractica-M"; 2008:313–324 (in Russ.).
19. Bleuer M. Endocrinologishe Psychiatril. Stuttgart: Thieme; 1954; 498:172–253.
20. Yurieva E.A., Vozdvizhenskaya E.S., Shabelnikova E.I. Stress. Adaptation syndrome. Participation in the pathogenesis of diseases in children Paediatrician practice. 2020;1:14–21 (in Russ.).
21. Lewis S., Lewis S.K. Child and stress. SPb.: Peter Press; 1997 (in Russ.).
22. Bremmer J.D. Stress and brain atrophy. CNS Neurol Disord Drug Targets. 2006;5(5):503–512. DOI: 10.2174/187152706778559309.
23. Madrigal J., Garcia-Bueno B., Caso J. et al. Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets. 2006;5(5):561–568. DOI: 10.2174/187152706778559327.
24. Kondrashova M.N., Zakharchenko M.V., Khunderyakova N.V. et al. What gives the doctor the definition of the functions of mitochondria in the lymphocytes of the patient. Innovative diagnostic methods in medicine. Novosibirsk: SibAK; 2013;10–58 (in Russ.).
25. Gnetneva E.S. Features of the state of health of children of the II dispensary group and the possibility of metabolic correction: thesis. M.; 2009 (in Russ.).
26. Sukhorukov V.S. Mitochondrial pathology and problems of the pathogenesis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2008;6:83–90 (in Russ.).
27. Brin I.L., Dunaikin M.L., Sheinkman O.G.. Elkar in a complex therapy of impairments of nervous and mental development of children with consequences of perinatal cerebral affections. Current Pediatrics. 2005;4(1):32–39 (in Russ.).
28. Klyuchnikov S., Il’yashenko D., Klyuchnikov M. Reasonable treatment of adolescents with l-carnitine and coenzyme Q10. Current Pediatrics. 2008;7(4):102–104 (in Russ.).
29. Sukhorukov V.S., Klyuchnikov S.O. Energotropic therapy in modern pediatrics. Vestnik pediatricheskoy farmacologii i nutritsiologii. 2006;6:4–9 (in Russ.).
30. Sukhorukov V.S. Essays on mitochondrial pathology. M.: "Medpraktika-M", 2011 (in Russ.).
31. Shalkevich L.V., Malash A.V. Metabolic therapy of diseases of the nervous system in children by carnitine-based medicinal product. Meditsinskie novosti. 2016;4:28–32 (in Russ.).
32. Neudakhin E.V. Substantiation of energotropic therapy of vegetative disorders in children. RMJ. 2018;2(II):107–112 (in Russ.).
33. Kalinina M.A., Kozlovskaya G.V., Kremneva L.F. Levocarnitine in pediatric practice. RMJ. Medical Review. 2018;10:40–44 (in Russ.).
34. Kuzin V.M. Carnitine chloride (25 years in clinical practice). RMJ. 2003;11(10):5–9 (in Russ.).
35. Brin I.L., Neudakhin E.V., Dunaikin M.L. Carnitine in Pediatrics: Research and Clinical Practice. M.: "Medpractica-M"; 2015 (in Russ.).
36. Hoppel Ch. The role of carnitine in normal and alterd fatty acid metabolism. Am J Kidney Dis. 2003;41(Suppl 4):S4–12. DOI: 10.1016/s0272-6386 (03) 00112-4.
37. Savica V., Calvani M., Benatti P. et al. Carnitine system in uremik patients. Molecular and clinical aspects. Semin Nephrol. 2004;24(5):464–468. DOI: 10.1016/j.semnephrol.2004.06.023.
38. Seim H., Eichler K., Kleber H. L-carnitine and its precursor, gammabyterobetaine. Nutraceuticals in Health and Disease Prevention. New York: Marcel Dekker Inc; 2001:217–256.
39. Binienda Z.K. Neuroprotective effects of L-carnitine in induced mitochondrial dysfunction. Ann N Y Acad Sci. 2003;993:289–295. DOI: 10.1111/j.1749-6632.2003.tb07536.x.
40. Dutta A., Ray K., Singh V. et al. L-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats. Exp Physiol. 2008;93:1139–1146. DOI: 10.1113/expphysiol.2008.042465.
41. Scott I. The role of mitochondria in the mammalian antiviral system. Mitochondrion. 2010;10:316–320. DOI: 10.1016/j.mito.2010.02.005.
42. Solarska K., Lewinska A., Karowicz-Bitinska A., Bartosz Gr. The antioxidant properties of carnitine in vitro. Cell Mol Biol Lett. 2010;15(1):90–97. DOI: 10.2478/s11658-009-0036-y.
43. Tebay L.E., Robertson H., Durant S.T. et al. Mechanism of activation of the transcription factor Nrf 2 by redox stressors, nutrientcues and energy status and the pathways through which it attenuates degenerative discase. Free Rad Biol Med. 2015;88:108–146. DOI: 10.1016/j.freeradbiomed.2015.06.021.
44. Ferreira G.C., Mckenna M.C. L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res. 2017;42(6):1661–1675. DOI: 10.1007/s11064-017-2288-7.
45. Xu Y., Jiang W., Chen G. et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. Adv Clin Exp Med. 2017;26(2):333–338. DOI: 10.17219/acem/61609.
46. Korovina N.A., Tvorogova T.M., Zakharova I.N. et al. The effectiveness of energotropic therapy in vegetative dystonia with cardiac changes in children and adolescents. Russian Bulletin of perinatology and pediatrics. 2008;6:21–29 (in Russ.).
47. Neudakhin E.V., Talitskaya O.E. On the expediency of using carnitine preparations in the treatment of vegetative dystonia syndrome in children. Paediatrician practice. 2017;1:52–59 (in Russ.).
48. Tvorogova T.M., Zakharova I.N., Korovina N.A. Correction of cardiac changes in vegetative dystonia in children and adolescents: emphasis on the effectiveness of energotropic therapy (in Russ.). (Electronic resource.) URL: http://www.medlinks.ru/article.php? Sid=43368 (access date: 10.15.2020).
49. Krapivkin A.I., Sukhorukov V.S. Possibilities of energotropic therapy for the correction of cognitive impairments in children. Paediatrician practice. 2009;1:49–52 (in Russ.).
50. Baedilova M.T., Lebed`kova S.E., Sumenko V.V. Clinical efficacy of energotropictherapy in children with chronic fatigue syndrome in case of connective tissue dysplasia. Medical news of north Caucasus. 2016;11(2):294–298 (in Russ.). DOI: 10.14300/mnnc.2016.11059
51. Safina T.V. Research of functional asymmetry of cerebral hemispheres in the regulation of ergotropic and trophotropic functions: Thesis. Ekaterinburg; 2015 (in Russ.).
52. Brin I.L., Dunaikin M.L., Sheinkman O.G. Vegetative regulation and neuropsychological syndromes in childhood. Journal of Asymmetry. 2014;8(4):6–23 (in Russ.).
2. Vegetative dysfunction in children and adolescents. L.V. Kozlova, ed. M.: GEOTAR-Media; 2008 (in Russ.).
3. Neudakhin E.V. On the issue of autonomic disorders in children (in order to discuss the problems raised in the article by A.A. Kurochkin et al. "Neurocirculatory dystonia in children and adolescents — a disease or borderline state"). Pediatria. 2003;2:101–103 (in Russ.).
4. Neudakhin E.V. Introduction. In: Shilyaev R.R., Neudakhin E.V., eds. Children’s Vegetology. M.: "Medpractica-M"; 2008:12–14 (in Russ.).
5. Batysheva T.T., Zaitsev K.A., Sarzhina M.N. et al. Autonomic dysfunction syndrome in children and adolescents: clinical manifestations, diagnosis and treatment. Part No. 1: guidelines No. 25. M.; 2015 (in Russ.).
6. Vein A.M. Autonomic disorders: clinical picture, treatment, diagnosis. M.: Medical Information Agency; 2000 (in Russ.).
7. Kryzhanovsky G.N., Magaeva S.V. Pathophysiology of neuroimmune interactions. Pathogenesis. 2010;1:4–9 (in Russ.).
8. Samotrueva M.A., Yasenyavskaya A.L., Tsibizova А.A. et al. Neuroimmunoendocrinology: modern concepts of molecular mechanisms. Immunologiya. 2017;38(1):49–59 (in Russ.). DOI: 10.18821/0206-4952-2017-38-1-49-59.
9. Korneva E.A. Pathways of neuro-immune communication: past and present time, clinical application. Medical Immunology (Russia). 2020;22(3):405–418 (in Russ.). DOI: 10.15789/1563-0625-PON-1974.
10. Neudakhin E.V. Chronic stress in general paediatric pathology. Pediatric Nutrition. 2014;12(5):44–49 (in Russ.)
11. Zavadenko N.N., Nesterovsky Yu.E. Clinical manifestations and treatment of autonomic dysfunction syndrome in children and adolescents. Pediatria. 2012;91(2):93–101 (in Russ.).
12. Neudakhin E.V. Basic concepts of vegetative dystonia syndrome in children and principles of treatment. Paediatrician practice. 2018;2:5–10 (in Russ).
13. Pankov D.D., Rumyantsev A.G. On the question of the definition of the terms "neurocirculatory dystonia" and "borderline state". Pediatria. 2003;2:98–100 (in Russ.).
14. Kryzhanovsky G.N. Determinant structures in the pathology of the nervous system. M.: Medicine; 1980 (in Russ.).
15. Dyukova G.M., Vein A.M. Autonomic dystonia syndrome. In: Golubev V.L., ed. Vegetative disorders: clinical picture, treatment, diagnosis: a guide for doctors. M.: Medical Information Agency; 2010:114–130 (in Russ.).
16. Antropov Yu.F., Shevchenko Yu.S. The role of affective disorders in the development of psychosomatic disorders in children. In: Shilyaev R.R., Neudakhin E.V., eds. Children’s Vegetology. M.: "Medpractica-M"; 2008:41–80 (in Russ.).
17. Sudakov K.V. Systemic mechanisms of emotional stress. M.: Medicine; 1981 (in Russ.).
18. Neudakhin E.V., Gromova S.V., Karmanov M.E. Peculiarities of psi-hovegetative homeostasis in adolescents with primary hypogonadism. In: Shilyaev R.R., Neudakhin E.V., eds. Children’s Vegetology. M.: "Medpractica-M"; 2008:313–324 (in Russ.).
19. Bleuer M. Endocrinologishe Psychiatril. Stuttgart: Thieme; 1954; 498:172–253.
20. Yurieva E.A., Vozdvizhenskaya E.S., Shabelnikova E.I. Stress. Adaptation syndrome. Participation in the pathogenesis of diseases in children Paediatrician practice. 2020;1:14–21 (in Russ.).
21. Lewis S., Lewis S.K. Child and stress. SPb.: Peter Press; 1997 (in Russ.).
22. Bremmer J.D. Stress and brain atrophy. CNS Neurol Disord Drug Targets. 2006;5(5):503–512. DOI: 10.2174/187152706778559309.
23. Madrigal J., Garcia-Bueno B., Caso J. et al. Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets. 2006;5(5):561–568. DOI: 10.2174/187152706778559327.
24. Kondrashova M.N., Zakharchenko M.V., Khunderyakova N.V. et al. What gives the doctor the definition of the functions of mitochondria in the lymphocytes of the patient. Innovative diagnostic methods in medicine. Novosibirsk: SibAK; 2013;10–58 (in Russ.).
25. Gnetneva E.S. Features of the state of health of children of the II dispensary group and the possibility of metabolic correction: thesis. M.; 2009 (in Russ.).
26. Sukhorukov V.S. Mitochondrial pathology and problems of the pathogenesis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2008;6:83–90 (in Russ.).
27. Brin I.L., Dunaikin M.L., Sheinkman O.G.. Elkar in a complex therapy of impairments of nervous and mental development of children with consequences of perinatal cerebral affections. Current Pediatrics. 2005;4(1):32–39 (in Russ.).
28. Klyuchnikov S., Il’yashenko D., Klyuchnikov M. Reasonable treatment of adolescents with l-carnitine and coenzyme Q10. Current Pediatrics. 2008;7(4):102–104 (in Russ.).
29. Sukhorukov V.S., Klyuchnikov S.O. Energotropic therapy in modern pediatrics. Vestnik pediatricheskoy farmacologii i nutritsiologii. 2006;6:4–9 (in Russ.).
30. Sukhorukov V.S. Essays on mitochondrial pathology. M.: "Medpraktika-M", 2011 (in Russ.).
31. Shalkevich L.V., Malash A.V. Metabolic therapy of diseases of the nervous system in children by carnitine-based medicinal product. Meditsinskie novosti. 2016;4:28–32 (in Russ.).
32. Neudakhin E.V. Substantiation of energotropic therapy of vegetative disorders in children. RMJ. 2018;2(II):107–112 (in Russ.).
33. Kalinina M.A., Kozlovskaya G.V., Kremneva L.F. Levocarnitine in pediatric practice. RMJ. Medical Review. 2018;10:40–44 (in Russ.).
34. Kuzin V.M. Carnitine chloride (25 years in clinical practice). RMJ. 2003;11(10):5–9 (in Russ.).
35. Brin I.L., Neudakhin E.V., Dunaikin M.L. Carnitine in Pediatrics: Research and Clinical Practice. M.: "Medpractica-M"; 2015 (in Russ.).
36. Hoppel Ch. The role of carnitine in normal and alterd fatty acid metabolism. Am J Kidney Dis. 2003;41(Suppl 4):S4–12. DOI: 10.1016/s0272-6386 (03) 00112-4.
37. Savica V., Calvani M., Benatti P. et al. Carnitine system in uremik patients. Molecular and clinical aspects. Semin Nephrol. 2004;24(5):464–468. DOI: 10.1016/j.semnephrol.2004.06.023.
38. Seim H., Eichler K., Kleber H. L-carnitine and its precursor, gammabyterobetaine. Nutraceuticals in Health and Disease Prevention. New York: Marcel Dekker Inc; 2001:217–256.
39. Binienda Z.K. Neuroprotective effects of L-carnitine in induced mitochondrial dysfunction. Ann N Y Acad Sci. 2003;993:289–295. DOI: 10.1111/j.1749-6632.2003.tb07536.x.
40. Dutta A., Ray K., Singh V. et al. L-carnitine supplementation attenuates intermittent hypoxia-induced oxidative stress and delays muscle fatigue in rats. Exp Physiol. 2008;93:1139–1146. DOI: 10.1113/expphysiol.2008.042465.
41. Scott I. The role of mitochondria in the mammalian antiviral system. Mitochondrion. 2010;10:316–320. DOI: 10.1016/j.mito.2010.02.005.
42. Solarska K., Lewinska A., Karowicz-Bitinska A., Bartosz Gr. The antioxidant properties of carnitine in vitro. Cell Mol Biol Lett. 2010;15(1):90–97. DOI: 10.2478/s11658-009-0036-y.
43. Tebay L.E., Robertson H., Durant S.T. et al. Mechanism of activation of the transcription factor Nrf 2 by redox stressors, nutrientcues and energy status and the pathways through which it attenuates degenerative discase. Free Rad Biol Med. 2015;88:108–146. DOI: 10.1016/j.freeradbiomed.2015.06.021.
44. Ferreira G.C., Mckenna M.C. L-carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res. 2017;42(6):1661–1675. DOI: 10.1007/s11064-017-2288-7.
45. Xu Y., Jiang W., Chen G. et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. Adv Clin Exp Med. 2017;26(2):333–338. DOI: 10.17219/acem/61609.
46. Korovina N.A., Tvorogova T.M., Zakharova I.N. et al. The effectiveness of energotropic therapy in vegetative dystonia with cardiac changes in children and adolescents. Russian Bulletin of perinatology and pediatrics. 2008;6:21–29 (in Russ.).
47. Neudakhin E.V., Talitskaya O.E. On the expediency of using carnitine preparations in the treatment of vegetative dystonia syndrome in children. Paediatrician practice. 2017;1:52–59 (in Russ.).
48. Tvorogova T.M., Zakharova I.N., Korovina N.A. Correction of cardiac changes in vegetative dystonia in children and adolescents: emphasis on the effectiveness of energotropic therapy (in Russ.). (Electronic resource.) URL: http://www.medlinks.ru/article.php? Sid=43368 (access date: 10.15.2020).
49. Krapivkin A.I., Sukhorukov V.S. Possibilities of energotropic therapy for the correction of cognitive impairments in children. Paediatrician practice. 2009;1:49–52 (in Russ.).
50. Baedilova M.T., Lebed`kova S.E., Sumenko V.V. Clinical efficacy of energotropictherapy in children with chronic fatigue syndrome in case of connective tissue dysplasia. Medical news of north Caucasus. 2016;11(2):294–298 (in Russ.). DOI: 10.14300/mnnc.2016.11059
51. Safina T.V. Research of functional asymmetry of cerebral hemispheres in the regulation of ergotropic and trophotropic functions: Thesis. Ekaterinburg; 2015 (in Russ.).
52. Brin I.L., Dunaikin M.L., Sheinkman O.G. Vegetative regulation and neuropsychological syndromes in childhood. Journal of Asymmetry. 2014;8(4):6–23 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
